The cofounder, president, and chief executive officer of Forge Biologics discussed the company’s approach to gene therapy manufacturing.
“If you wanted to treat just 25% of the patients out there with muscular dystrophy, it would take most of the bioreactors on the East Coast running Day and night for a year just to treat that. And that'sonly for one indication. So, Forge and the team came together to build more GMP suites and more bioreactors at larger volumes to try to help meet a lot of that unmet patient need.”
Forge Biologics is supporting gene therapy development with a dual approach, both as a contract development and manufacturing company as well as a developer of the Krabbe A gene therapy FBX101, which is currently being evaluated in the phase 1/2 RESKUE clinical trial (NCT04693598).
Forge also recently announced the formation of an independent scientific and manufacturing advisory board composed of gene therapy leaders to advise on the company’s pipeline development and gene therapy manufacturing offerings.
CGTLive spoke with Tim Miller, PhD, cofounder, president, and chief executive officer, Forge Biologics, to learn more about the company. He discussed Forge’s approach to manufacturing, the new scientific board, and the Krabbe A program, and touched on presentations from the American Society of Gene & Cell Therapy 25th Annual Meeting.